Clinical Edge Journal Scan

Metastatic CRC: Foods rich in vegetable fats prolong survival


 

Key clinical point: The risk for all-cause mortality and cancer progression or death is lower among patients with metastatic colorectal cancer (CRC) and a higher intake of vegetable fats.

Major finding: Patients with the highest (23.5% kcal/day; interquartile range [IQR] 21.6%-25.7% kcal/day) vs lowest (11.6% kcal/day; IQR 10.1%-12.7% kcal/day) median intake of vegetable fats showed a lower risk for all-cause mortality (adjusted hazard ratio [aHR] 0.79; 95% CI 0.63-1.00) and cancer progression or death (aHR 0.71; 95% CI 0.57-0.88).

Study details: Findings are from a prospective analysis that included 1149 patients with metastatic CRC from the CALGB 80405 (Alliance)/SWOG 80405 study .

Disclosures: This study was supported by the US National Cancer Institute of the National Institutes of Health and partly by Bristol Myers Squibb, Genentech, Pfizer, and Sanofi. Some authors declared serving as advisory board members or consultants for or receiving research support or payments for research advice or services from various sources, including Pfizer and Genentech.

Source: Van Blarigan EL et al. Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405. Int J Cancer. 2022 (Jul 29). Doi: 10.1002/ijc.34230

Recommended Reading

Baseline albumin level may predict PD-1 blockade-induced hyperprogressive disease in advanced gastric cancer
MDedge Hematology and Oncology
Neoadjuvant chemotherapy for gastric cancer: Determining factors with a prognostic impact
MDedge Hematology and Oncology
RHOA expression linked with clinical features in gastric cancer
MDedge Hematology and Oncology
High-dose vitamin C prolongs the PFS of patients with RAS mutation
MDedge Hematology and Oncology
Locally advanced rectal cancer: mFOLFOXIRI chemotherapy reduces the need for radiotherapy
MDedge Hematology and Oncology
No increase in second cancer development after additive chemotherapy for colon cancer
MDedge Hematology and Oncology
First-line bevacizumab better than cetuximab/panitumumab in right-sided RAS WT mCRC
MDedge Hematology and Oncology
Increasing CRC incidence: Can chemopreventive agents come to the rescue?
MDedge Hematology and Oncology
Specific clinical features indicate more timely prediagnostic investigations or referral for CRC
MDedge Hematology and Oncology
How efficient is neoadjuvant chemotherapy in mismatch repair deficient colon cancer?
MDedge Hematology and Oncology